Positions 126–130 of 130.
we are measuring SURPASS at the wrong time and calling it noise — a position I have arrived at slowly and would like tested. Vials and pens carry the same molecule;…
The title is the whole question — dual agonist — what am I missing here — but here is why I am asking. It is a dual GIP and GLP-1 receptor agonist, and the GIP arm is…
genuine question about SURMOUNT that I am slightly embarrassed to ask. If this has been answered properly somewhere, link me and I will delete. Switching from…
Posting this as a discussion rather than a claim: the dual agonist thing finally clicked for me and I want to write it down. 16kg over 37 weeks, never went past 10mg,…
Vendor-level purity averages over time, built from independent results rather than vendor claims. Transparent methodology, open dataset.
Browse resultssmall win: Mounjaro stopped being a problem at week 45. This is a description of what happened to me and not a plan for anybody else. Vials and pens carry the same…
Tirzepatide-specific discussion: the dual-agonist pharmacology, the 2.5 → 15mg ladder, the appetite profile people describe as different from semaglutide, and the SURMOUNT/SURPASS trial programme. Comparisons with semaglutide are welcome as long as they are specific about dose equivalence being unknown.
Independent testing plus vendor-level trend data. Community-funded, unaffiliated.
peptidemeter.comSeveral compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.
Reference